

1 April 2016

Extension of Omniblend Innovation Tranche 2 Settlement Deadline

Highlights

- EVE Investments has successfully extended its tranche 2 settlement deadline with Omniblend Innovation to better align the date with Omniblend Innovation's cash requirements
- Completion of tranche 1 investment on-track for April 2016

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on Omniblend Innovation, the medical technology company focused on foods for special medical purposes, in which EVE is acquiring a ~40% holding, subject to certain conditions (see ASX announcement on 17 December 2015).

EVE and Omniblend Innovation have negotiated an extension to the settlement of the tranche 2 investment which better aligns Omniblend Innovation's requirement for cash with the timing of the investment.

Under the revised terms, payment for tranche 2 will be made on the earlier of 30 days after Omniblend Innovation's cash reserves falling below A\$500,000, or 30 September 2016.

Additionally, the Company has extended the settlement for tranche 1 to be no later than 30 April 2016. This extension is to provide time for the execution of the Shareholder Agreement by all parties. Settlement is on-track to be completed during April.

-ENDS-

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au

Justin Kelly
Media & Capital Partners
0408 215 858
justin.kelly@mcpartners.com.au

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au